<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03685942</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH 2017-02</org_study_id>
    <nct_id>NCT03685942</nct_id>
  </id_info>
  <brief_title>Efficacy of Light Therapy Device LUMINETTE® in Major Depressive Disorder</brief_title>
  <acronym>LUMIDEP</acronym>
  <official_title>Efficacy of Light Therapy Device LUMINETTE® in Major Depressive Disorder(LUMIDEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Psychothérapique de Nancy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LUCIMED</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Psychothérapique de Nancy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of light therapy with LUMINETTE device to usual treatment
      (antidepressant drug and psychotherapy) in the treatment of Major Depressive Disorder (MDD).
      Half of the participants will receive active light therapy with LUMINETTE device while the
      other half will receive placebo light therapy with LUMINETTE placebo device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depressive disorder (MDD) is a world wide spread disorder. According to the World
      health organization, MDD affects more than 300 million people of all ages in the world.
      Treatments of MDD include pharmacological treatment and psychotherapy. Pharmacological
      treatments, mostly serotonin selective reuptake inhibitors, have a delayed onset of action,
      require long-term treatment and have partial efficacy. In fact, only one third of patients
      respond to the first antidepressant treatment and two-third after multiple trials. So, there
      is a need for new treatment strategy.

      Light therapy is a well established non pharmacological treatment of seasonal affective
      disorder, a clinical subtype of affective disorder characterized by recurrent episodes of MDD
      occurring with a seasonal pattern. Patients are exposed to artificial light for a variable
      duration and intensity. Although the precise mechanism of bright light therapy remains
      unknown, it is thought to act through the eyes by activating the suprachiasmatic nucleus, the
      principal circadian pacemaker.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Åsberg depression rating scale (MADRS)</measure>
    <time_frame>week 8</time_frame>
    <description>Rating scale measuring depressive symptoms. Each item is scored from 0 to 3, yielding a total between 0 and 27.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>week 8</time_frame>
    <description>Self reported rating scale measuring quality of sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>week 8</time_frame>
    <description>Self reported rating scale measuring day time sleepiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>week 8</time_frame>
    <description>Tool measuring the severity of anxiety symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>electroretinogramm</measure>
    <time_frame>at inclusion, week 4,8 and 12</time_frame>
    <description>test that measure the functional activity of the retina</description>
  </other_outcome>
  <other_outcome>
    <measure>Hopkins Verbal Learning Test (HVLT)</measure>
    <time_frame>week 10</time_frame>
    <description>test of verbal Learning and memory</description>
  </other_outcome>
  <other_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>week 10</time_frame>
    <description>screening assessment for detecting cognitive impairment</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroop test</measure>
    <time_frame>week 10</time_frame>
    <description>test assessing the ability to inhibit cognitive interference</description>
  </other_outcome>
  <other_outcome>
    <measure>Trail Making Test (TMT)</measure>
    <time_frame>week 10</time_frame>
    <description>test evaluating executive functions</description>
  </other_outcome>
  <other_outcome>
    <measure>Wechsler Adult Intelligence Scale subtest (WAIS)</measure>
    <time_frame>week 10</time_frame>
    <description>test evaluating memory</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Unipolar Depression</condition>
  <arm_group>
    <arm_group_label>active light therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Light therapy 1000 lux daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m., during 8 weeks in addition to usual treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo light therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>People receive usual treatment and use a placebo light therapy device (50 lux) daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m. during 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>active light therapy (LUMINETTE®)</intervention_name>
    <description>light therapy on a portable light visor device</description>
    <arm_group_label>active light therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo light therapy</intervention_name>
    <description>placebo portable light visor device</description>
    <arm_group_label>placebo light therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depressive disorder assessed with DSM-IV criteria evaluated with the french
             version of the Mini International Neuropsychiatric Interview (MINI).

        Exclusion Criteria:

          -  Others evolutive psychiatric disease (DSM-IV axis I evaluated with the MINI) except
             anxiety disorders

          -  No usual routine treatment of major depressive disorder

          -  Previous or actual treatment with light therapy

          -  Seasonal major depressive disorder

          -  Suicidal risk

          -  Active neurologic disease

          -  Retinal pathology

          -  Pregnant women

          -  Breastfeeding women

          -  Psychiatric care without consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas SCHWITZER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Psychothérapique de Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eve COSKER</last_name>
    <phone>+33383925034</phone>
    <email>eve.cosker@cpn-laxou.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatiana DABROWSKI</last_name>
    <phone>+33383925349</phone>
    <email>tatiana.dabrowski@cpn-laxou.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Psychothérapique de Nancy</name>
      <address>
        <city>Laxou</city>
        <zip>54200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eve COSKER</last_name>
      <email>eve.cosker@cpn-laxou.com</email>
    </contact>
    <contact_backup>
      <last_name>Thomas SCHWITZER</last_name>
      <email>thomas.schwitzer@cpn-laxou.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>light therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

